Hangzhou Hanx Biopharmaceuticals, Ltd.
6 clinical trials · Sponsor
◉ Watch Hangzhou Hanx Biopharmaceuticals, Ltd.
| Record | Firm | Date |
|---|---|---|
| HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours (NCT06708663) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2025-01-17 |
| A Phase 2 Study of HX301 in Patients with High-grade Giloma (NCT06703255) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2025-01-08 |
| Recombinant Humanized Anti-CD47/PD-1 Bifunctional Antibody HX009 in Patients With Relapsed/Refractory Lymphoma (NCT05189093) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2021-12-31 |
| Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid Tumors (NCT04886271) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2021-05-12 |
| The Tolerability and Pharmacokinetics of HX301 Monolactate Capsules in Patients With Advanced Solid Tumors (NCT05731934) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2020-09-15 |
| Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors (NCT05731752) | Hangzhou Hanx Biopharmaceuticals, Ltd. | 2020-05-28 |
Track Hangzhou Hanx Biopharmaceuticals, Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.